ONCY Stock Analysis: Buy, Sell, or Hold?
ONCY - Oncolytics Biotech, Inc. Common Shares
$0.88
-0.05 (-5.13%)
▼
5d:
-2.22%
30d:
-5.13%
90d:
-16.98%
BUY
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ONCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called ONCY this week
83% bullish • 1 bearish
83% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ONCY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ONCY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ONCY is currently trading at $0.88, which is considered fair relative to its 30-day fair value range of $0.82 to $0.95.
Technical Outlook: Technically, ONCY is in a downtrend. Immediate support is located at $0.77, while resistance sits at $1.18. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.36 (+509.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ONCY is in a downtrend. Immediate support is located at $0.77, while resistance sits at $1.18. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.36 (+509.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.82 -
$0.95
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 509.2% below Wall St target ($5.36)
Trading Range Analysis
30-Day Trading Range
$0.82 -
$0.95
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.77
Resistance Level
$1.18
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.43
Wall Street Target
$5.36
(+509.2%)
Share & Embed Analysis
Last updated: June 03, 2026 6:52 PM ET
Data refreshes hourly during market hours. Next update: 7:52 PM
Data refreshes hourly during market hours. Next update: 7:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONCY showing a specific setup today?
Insider Activity (6 Months)
14
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jared Kelly
BUY
5050 shares
2026-03-12
James T Parsons
BUY
10000 shares
2026-03-11
Allison Hagerman
BUY
10000 shares
2026-02-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
